Midazolam Bp Accord Healthcare (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor, increasing chloride ion flow into neurons. This amplifies inhibitory signals, leading to reduced neuronal firing and producing sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.

The dose of Midazolam Bp Accord Healthcare is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended procedure. Only a qualified health professional should set the appropriate dosing regimen.

Midazolam is classified as pregnancy category unknown, and its safety for the fetus or nursing infant has not been established. Use during pregnancy or lactation should only occur if the potential benefit justifies the potential risk, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Midazolam is a short‑acting benzodiazepine offering rapid onset and easy titration, which distinguishes it from longer‑acting agents like diazepam. Compared with propofol, it provides less cardiovascular depression but may cause more respiratory depression when combined with other CNS depressants.

Midazolam Bp Accord Healthcare should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency.

The product is supplied as an injectable solution for intravenous administration. It is typically given by a trained healthcare professional, who can adjust the infusion rate or bolus dose according to the patient’s response and the clinical setting.

The most serious risks include profound respiratory depression, severe hypotension, and paradoxical reactions such as agitation or aggression. These events require immediate medical attention and continuous monitoring, especially when the drug is used with other depressant substances.

Patients with known hypersensitivity to benzodiazepines, those with severe respiratory insufficiency, or individuals taking interacting CNS depressants without appropriate monitoring should avoid Midazolam. Additionally, it is contraindicated in patients with acute narrow‑angle glaucoma.